Scholarlink

<p>The aim of this study was to evaluate the 10-year risk of revision surgery following total hip (THA) and knee (TKA) arthroplasty in patients with inflammatory arthritis (IA) receiving perioperative methotrexate (MTX) monotherapy and to compare their outcomes with those of propensity score–matched patients undergoing arthroplasty for osteoarthritis. We conducted a retrospective study using data from the Emilia-Romagna Orthopedic Arthroplasty Implants Register. The primary cohort included patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis residing in Emilia-Romagna (Italy) who underwent primary THA or TKA and received at least one prescription of MTX within 90 days before or after surgery. The control cohort consisted of propensity score-matched patients who underwent THA/TKA for osteoarthritis. The perioperative MTX-treated IA group included 225 patients who underwent THA and 215 patients who underwent TKA. The control group consisted of 449 patients with osteoarthritis who received THA and 428 patients who received TKA. Implant survival rates at 10 years were not significantly different when comparing IA patients perioperatively treated with MTX monotherapy and matched osteoarthritis patients, in either those who underwent THA or TKA. This remained consistent when accounting for competing risk of death. These findings suggest that patients with IA receiving perioperative MTX monotherapy have 10-year revision outcomes comparable to those of propensity score–matched patients with osteoarthritis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ten-year hip and knee arthroplasty implant survival in patients with inflammatory arthritis receiving methotrexate monotherapy compared with osteoarthritis: a registry-based data linkage study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月15日

查看全文
  • Francesco Ursini,
  • Barbara Bordini,
  • Jacopo Ciaffi,
  • Umberto Santoro,
  • Federico Ruta,
  • Roberto Caporali,
  • Alberto Di Martino,
  • Cesare Faldini

摘要

The aim of this study was to evaluate the 10-year risk of revision surgery following total hip (THA) and knee (TKA) arthroplasty in patients with inflammatory arthritis (IA) receiving perioperative methotrexate (MTX) monotherapy and to compare their outcomes with those of propensity score–matched patients undergoing arthroplasty for osteoarthritis. We conducted a retrospective study using data from the Emilia-Romagna Orthopedic Arthroplasty Implants Register. The primary cohort included patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis residing in Emilia-Romagna (Italy) who underwent primary THA or TKA and received at least one prescription of MTX within 90 days before or after surgery. The control cohort consisted of propensity score-matched patients who underwent THA/TKA for osteoarthritis. The perioperative MTX-treated IA group included 225 patients who underwent THA and 215 patients who underwent TKA. The control group consisted of 449 patients with osteoarthritis who received THA and 428 patients who received TKA. Implant survival rates at 10 years were not significantly different when comparing IA patients perioperatively treated with MTX monotherapy and matched osteoarthritis patients, in either those who underwent THA or TKA. This remained consistent when accounting for competing risk of death. These findings suggest that patients with IA receiving perioperative MTX monotherapy have 10-year revision outcomes comparable to those of propensity score–matched patients with osteoarthritis.